Sugi Predict

Sugi Predict / Targets / ABHD11

ABHD11

sn-1-specific diacylglycerol lipase ABHD11 · Q8NFV4 · ABHD11 on Sugi Atlas →

54 patent compounds predicted against ABHD11, 45 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30307838 SCHEMBL30307838 0.59 1/20
SCHEMBL31106406 SCHEMBL31106406 0.52 1/20
SCHEMBL18935617 SCHEMBL18935617 0.51 1/20
SCHEMBL2318391 SCHEMBL2318391 0.49 1/20
SCHEMBL28070422 SCHEMBL28070422 0.49 1/20
SCHEMBL22978799 SCHEMBL22978799 0.48 1/20
SCHEMBL18935811 SCHEMBL18935811 0.46 1/20
SCHEMBL1198628 SCHEMBL1198628 0.45 1/20
SCHEMBL9198531 SCHEMBL9198531 0.45 1/20
SCHEMBL12799869 SCHEMBL12799869 0.45 1/20
SCHEMBL13431500 SCHEMBL13431500 0.44 1/20
SCHEMBL5991860 SCHEMBL5991860 0.43 1/20
SCHEMBL7762330 SCHEMBL7762330 0.43 1/20
SCHEMBL10995253 SCHEMBL10995253 0.43 1/20
SCHEMBL14457237 SCHEMBL14457237 0.42 1/20
SCHEMBL15456860 SCHEMBL15456860 0.42 1/20
SCHEMBL18675855 SCHEMBL18675855 0.42 1/20
SCHEMBL9195659 SCHEMBL9195659 0.42 1/20
SCHEMBL9195662 SCHEMBL9195662 0.42 1/20
SCHEMBL9199780 SCHEMBL9199780 0.42 1/20

Clinical trials — most relevant to ABHD11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis PHASE4COMPLETED
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency PHASE3COMPLETED
Betaine and Peroxisome Biogenesis Disorders PHASE3COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Orlistat for the Treatment of Type I Hyperlipoproteinemia PHASE2COMPLETED
Pharmacogenetics of Disulfiram for Cocaine PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
Lipodystrophy Connect Patient Registry nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease. nanUNKNOWN
Abnormal Lipids - Causes and Effects nanRECRUITING
for Adipose Tissue DIabetes VAriants (fATDIVA) nanCOMPLETED
Identification of a New Gene Involved in Hereditary Lipodystrophy nanCOMPLETED
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD. nanENROLLING_BY_INVITATION
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children nanNOT_YET_RECRUITING
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Nutritional Ketosis: a Novel Metabolic Strategy to Treat Lymphedema Patients? nanRECRUITING
Genes Involved in Lipid Disorders nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
A Longitudinal Study on Short-term Effects of Gastric Bypass on Glucose Homeostasis in Obesity nanCOMPLETED
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects) nanUNKNOWN
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
Shwachman Diamond Syndrome Registry and Study nanRECRUITING
The Classification and Cause of Leukodystrophies of Unknown Cause nanCOMPLETED
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ABHD11 binder may also engage these)

ProteinNameSimilarity
Q8K4F5 — 1.000 Q8K4F5 →
Q3SZ73 — 0.988 Q3SZ73 →
Q0V9K2 — 0.981 Q0V9K2 →
Q6DRD9 — 0.977 Q6DRD9 →
Q86TX2 — 0.976 Q86TX2 →
Q9BSH5 — 0.974 Q9BSH5 →
Q9QYR9 — 0.974 Q9QYR9 →
Q2TAP9 — 0.974 Q2TAP9 →
Q17QK8 — 0.973 Q17QK8 →
O95396 — 0.973 O95396 →
Q86U10 — 0.972 Q86U10 →
Q6Q2Z6 — 0.972 Q6Q2Z6 →
O55171 — 0.972 O55171 →
A5GFZ6 — 0.970 A5GFZ6 →
Q3SZ07 — 0.970 Q3SZ07 →
Q8MIR4 — 0.969 Q8MIR4 →
P51840 — 0.969 P51840 →
TARS2 Threonine--tRNA ligase, mitochondrial 0.969 landscape →
O55137 — 0.968 O55137 →
HSD17B1 17-beta-hydroxysteroid dehydrogenase type 1 0.968 landscape →
Q8R123 — 0.968 Q8R123 →
A0JNU3 — 0.968 A0JNU3 →
P55203 — 0.968 P55203 →
P51839 — 0.968 P51839 →
P49753 — 0.967 P49753 →
Q9QYR7 — 0.967 Q9QYR7 →
Q96AB3 — 0.967 Q96AB3 →
Q9Y3E2 — 0.967 Q9Y3E2 →
Q865R1 — 0.967 Q865R1 →
Q9CYW4 — 0.967 Q9CYW4 →